© Copyright RiverVest® All Rights Reserved.
/ NEWSLETTER
Newsletter Archive
2025
RiverVest Newsletter – February 2025
- A Celebration of 25 Years in 2025
- New Investment: Atalanta Therapeutics
- Diabetes Treatment: A Story of Complicated Progress and Great Potential
- Scientific Advisory Board Update
2024
Year in Review – December 2024
- Investment Updates and Portfolio Company Progress
- Promotions: Andrew Kleiboeker and Jeff Seitz
- John Cambier and Gary DeCrescenzo join RiverVest Scientific Advisory Board
- Pharma Industry Outlook
RiverVest Newsletter – October 2024
- Welcome: Nafise Masoumi, Ph.D., joins RiverVest as Senior Associate
- RiverVest Team Culture
- Tom Melzer Expert Insight: Experienced Management Team Helps Mitigate Risk
- Meet the Leader: Lyn Baranowski, CEO of Avalyn Pharma
- Portfolio News
RiverVest Newsletter – June 2024
- 2024 Annual Meeting Recap
- Tim Opler, Ph.D., Keynote on State of the Pharma Industry
- Presenters: Avalyn’s Lyn Baranowski, Intervene’s Jeff Elkins, Engrail’s Vikram Sudarsan, Wugen’s Jan Davidson
- Square Founder Jim McKelvey Talks Glass Blowing, Right Timing
- Niall O’Donnell Honored by UC San Diego’s Rady School of Management
- Company Spotlight: Engrail Therapeutics Addresses Anxiety Disorders
- Portfolio News
RiverVest Newsletter – March 2024
- New Investment: Engrail Therapeutics (Neuropsychiatric / Biopharma)
- Promotions: Karen Spilizewski, Isaac Zike and Pascal Krotee
- Expert Insight: Alleviant Trial Investigates Novel Heart Failure Treatment
- Another FDA Approval for Mirum Pharmaceuticals
- Portfolio News
2023
RiverVest Newsletter – November 2023
- Pascal Krotee Wins Life Science Catalyst Award
- Case Study: Good Therapeutics (Conditionally Active Protein Technology)
- Expert Insight: Mitochondrial Challenges and Innovations
- PBS Medical Stories Documentary Shines Light on Alagille Syndrome
- Portfolio News
RiverVest Newsletter – June 2023
- 2023 Annual Meeting Recap
- Joel Prakken, Ph.D., Keynote on Current Economic Outlook
- Presenters: Alleviant’s Adam Berman, Bluejay’s Keting Chu, Bonum’s Diane Hollenbaugh, Sparrow’s Robert Jacks
- Year in Review
- Niall O’Donnell Expert Insight: Orphan Drug Act of 1983
- Portfolio News
RiverVest Newsletter – March 2023
- New Investment: Alleviant Medical (Heart Failure / Device)
- Tom Melzer Expert Insight: Managing Risks, Maximizing Returns
- In Memoriam: William A. Peck, M.D.
- Portfolio News
2022
RiverVest Newsletter – November 2022
- Investment Updates and Portfolio Company Progress
- Company Acquisition: Good Therapeutics by Roche
- Company Acquisition: Standard Bariatrics by Teleflex
- Case Study: Mirum Pharmaceuticals (Rare Liver Diseases)
- Jay Schmelter on NVCA Webinar on St. Louis Innovation Ecosystem
- Portfolio News
RiverVest Newsletter – June 2022
- 2022 Annual Meeting Recap
-
- Alessandro Sette, Dr. Biol. Sci., Keynote on SARS-CoV-2 Immune Response Data
- Presenters: Mirum’s Chris Peetz, Standard Bariatrics’ Matt Sokany, Biolinq’s Rich Yang, Arch’s Laurence Blumberg, Xilio’s
-
- Promotions: Isaac Zike and Curtis Rother
- Welcome: Pascal Krotee, Ph.D., Joins RiverVest as Senior Associate; Courtney Harris as Controller; and Jeff Seitz as Analyst
- Portfolio News
2020
RiverVest Newsletter – August 2020
- RiverVest Celebrates 20 Years of Science, Strategy and Innovation
- 2022 Annual Meeting Recap
- Welcome: Andrew Kleiboeker joins RiverVest as Analyst
- Portfolio News
2019
RiverVest Newsletter – Spring 2019
- RiverVest closes on its oversubscribed $184.4 million RiverVest Fund IV
- RiverVest recognized as Investor of the Year by the St. Louis Business Journal
- Welcome: Sivan Weitzman joins RiverVest as Chief Financial Officer
- Portfolio News
2017
RiverVest Newsletter – December 2017
- RiverVest Expands Scientific Advisory Board – Ronald T. Borchardt, PhD and Jared Rutter, PhD
- Portfolio News
RiverVest Newsletter – February 2017
- RiverVest Closes on $15 Million Biopharma Seed Fund
- Welcome: Karen Gheesling Mullis joins RiverVest as Venture Partner
- Portfolio News
2016
RiverVest Newsletter – September 2016
- RiverVest Venture Partners Co-leads $86 Million Series A Financing for St. Louis-founded Startup Tioma
- RiverVest’s Fund II Continues to Perform in Top 5% of VC Funds
- Welcome: Nakul Tandon joins RiverVest as Analyst
- Portfolio News
RiverVest Newsletter – May 2016
- Nancy Hong Joins RiverVest as Managing Director
- RiverVest Fund III has Strong Start
- RiverVest Fund II Performs in Top 5% of VC Funds
- Portfolio News